{"id":"dccr","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CDK8 is a component of the Mediator complex, which plays a key role in regulating gene transcription. By inhibiting CDK8, DCCR aims to modulate the expression of genes involved in various diseases.","oneSentence":"DCCR is a small molecule that inhibits the activity of the CDK8 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:43.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors with high CDK8 expression"}]},"trialDetails":[{"nctId":"NCT07450664","phase":"","title":"Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome","status":"ENROLLING_BY_INVITATION","sponsor":"Soleno Therapeutics, Inc.","startDate":"2025-11-26","conditions":"Prader-Willi Syndrome","enrollment":200},{"nctId":"NCT05701774","phase":"PHASE3","title":"Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Soleno Therapeutics, Inc.","startDate":"2023-01-31","conditions":"Prader-Willi Syndrome","enrollment":83},{"nctId":"NCT03714373","phase":"PHASE3","title":"Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-10-01","conditions":"Prader-Willi Syndrome","enrollment":115},{"nctId":"NCT03440814","phase":"PHASE3","title":"A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Soleno Therapeutics, Inc.","startDate":"2018-05-09","conditions":"Prader-Willi Syndrome","enrollment":127},{"nctId":"NCT05532020","phase":"PHASE2","title":"An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities","status":"UNKNOWN","sponsor":"Soleno Therapeutics, Inc.","startDate":"2023-01","conditions":"SH2B1 Deficiency Obesity, Obesity Associated With PCSK1 Mutation (rs6232 Variant), SIM1 Deficiency Obesity","enrollment":30},{"nctId":"NCT04086810","phase":"PHASE3","title":"An Open-Label Study of DCCR Tablet in Patients With PWS","status":"WITHDRAWN","sponsor":"Soleno Therapeutics, Inc.","startDate":"2019-10","conditions":"Prader-Willi Syndrome","enrollment":""},{"nctId":"NCT02893618","phase":"PHASE2","title":"A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)","status":"UNKNOWN","sponsor":"Essentialis, Inc.","startDate":"2017-07","conditions":"Prader-Willi Syndrome","enrollment":32},{"nctId":"NCT00973271","phase":"PHASE3","title":"Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides","status":"WITHDRAWN","sponsor":"Essentialis, Inc.","startDate":"2011-03","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT02034071","phase":"PHASE1, PHASE2","title":"Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2014-04","conditions":"Prader-Willi Syndrome","enrollment":13},{"nctId":"NCT00901823","phase":"PHASE1","title":"Open-Label, Single- and Multiple-Dose Pharmacokinetic Study of Diazoxide Choline","status":"WITHDRAWN","sponsor":"Essentialis, Inc.","startDate":"2011-03","conditions":"Hypertriglyceridemia","enrollment":""},{"nctId":"NCT01211847","phase":"PHASE2","title":"Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridemia, Dyslipidemia","enrollment":44},{"nctId":"NCT01211860","phase":"PHASE1","title":"Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects","status":"COMPLETED","sponsor":"Essentialis, Inc.","startDate":"2010-10","conditions":"Hypertriglyceridmia","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diazoxide Choline Controlled-Release Tablet"],"phase":"phase_3","status":"active","brandName":"DCCR","genericName":"DCCR","companyName":"Essentialis, Inc.","companyId":"essentialis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DCCR is a small molecule that inhibits the activity of the CDK8 protein. Used for Solid tumors with high CDK8 expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}